article Open AccessTop 10% cited
The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways
Journal of Pharmacology and Experimental Therapeutics · 2003 · Vol. 306(3) · pp. 954–964
Mark J. Millan✉(AVL (France))Alain P. GobertF. LejeuneA DekeyneAdrian Newman‐TancrediValérie PasteauJean‐Michel RivetDidier Cussac
Circadian rhythm and melatoninNeuroendocrine regulation and behaviorNeurotransmitter Receptor Influence on BehaviorAgomelatineAgonistReceptorEndocrinologyInternal medicineChemistryDopamineDopaminergicIdazoxanPharmacology
MeSH terms
AcetamidesAnimalsBinding SitesCorpus StriatumDopamineElectrophysiologyFrontal LobeMaleMelatoninNaphthalenesSynaptic TransmissionNeuronsNorepinephrineNucleus AccumbensPenile Erection
Citations
509
FWCI
4.35
field-weighted impact
References
55
Percentile
96%
vs. same field & year
Citations per year
References
Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor Stimulus
Molecular Pharmacology · 1998 · 512 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.